ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which¬† stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

read more

Clinical trial programme with new c-Met inhibitor for kidney cancer initiated in Australia and New Zealand

CBT Pharmaceuticals (a US and China-based biopharmaceutical company) announced the launch of its APOLLO Oncology Clinical Trials Programme this week. The APOLLO series of trials will investigate whether the c-Met inhibitor, bozitinib (CBT-101) can work in combination with immunotherapies to improve response rates and patient outcomes. The first study in the APOLLO programme has been […]

read more
Showing all 2 results